Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma.

Aurore DumondEtienne BrachetJérôme DurivaultValérie VialAnna K PuszkoYves LepelletierChristopher MontemagnoMarina Pagnuzzi-BoncompagniOlivier HermineChristiane GarbayNathalie LagardeMatthieu MontesLuc DemangeRenaud GrépinGilles Pagès

Published in: Journal of experimental & clinical cancer research : CR (2021)

Our study strongly suggests that inhibiting NRPs is a relevant treatment for mccRCC patients in therapeutic impasses and NRPa-308 represents a relevant hit.

Keyphrases

end stage renal disease
metastatic renal cell carcinoma
chronic kidney disease
newly diagnosed
ejection fraction
gene expression
dna methylation
prognostic factors
patient reported outcomes
replacement therapy